English
Regional settings| Spread | 0.09 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 18.97 |
| Open | 18.82 |
| 1-Year Change | 75.89% |
| Day's Range | 18.82 - 19.61 |
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company’s segment is engaged in discovery and development of medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and hematologic indications. It is developing KO-539, a small molecule inhibitor of the Lysine K-specific Methyltransferase 2A (KMT2A) interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
BRIEF: For the fiscal year ended 31 December 2021, Kura Oncology Inc revenues was not reported. Net loss increased 46% to $130.5M. Higher net loss reflects General and administrative - Balancing increase of 35% to $30.4M (expense), Stock-based Compensation in SGA increase of 82% to $16.1M (expense), Share-based compensation increase of 88% to $7.5M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.69 to -$1.97.
